Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3395 | Rosuvastatin + BAY1817080 Wiki | 0.35 |
| drug352 | Artesunate Wiki | 0.35 |
| drug1700 | Health-related quality of life Wiki | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4816 | ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF. Wiki | 0.35 |
| drug4448 | ctDNA blood sampling Wiki | 0.35 |
| drug349 | Artemisia Annua Leaf Wiki | 0.35 |
| drug3350 | Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening Wiki | 0.35 |
| drug1444 | Exercise capacity Wiki | 0.35 |
| drug347 | Artemesia annua Wiki | 0.35 |
| drug2216 | Lung Function tests Wiki | 0.35 |
| drug1445 | Exercise physiology Wiki | 0.35 |
| drug4800 | vadadustat Wiki | 0.35 |
| drug3735 | Standard of Care Treatment Wiki | 0.35 |
| drug2273 | MagPro X100 Stimulator, B70 Fluid-Cooled Coil Wiki | 0.25 |
| drug3588 | Serological test Wiki | 0.20 |
| drug3392 | Rosuvastatin Wiki | 0.18 |
| drug4650 | placebo Wiki | 0.09 |
| drug2029 | Ivermectin Wiki | 0.08 |
| drug2981 | Placebo oral tablet Wiki | 0.06 |
| drug2916 | Placebo Wiki | 0.06 |
| drug3728 | Standard of Care Wiki | 0.06 |
| drug1775 | Hydroxychloroquine Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001528 | Behcet Syndrome NIH | 0.50 |
| D046152 | Gastrointestinal Stromal Tumors NIH | 0.35 |
| D056660 | Hereditary Autoinflammatory Diseases NIH | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D010505 | Familial Mediterranean Fever NIH | 0.35 |
| D002006 | Brucellosis NIH | 0.35 |
| D001661 | Biliary Tract Neoplasms NIH | 0.35 |
| D001749 | Urinary Bladder Neoplasms NIH | 0.35 |
| D012507 | Sarcoidosis NIH | 0.25 |
| D009220 | Myositis NIH | 0.25 |
| D001714 | Bipolar Disorder NIH | 0.25 |
| D012859 | Sjogren's Syndrome NIH | 0.18 |
| D015179 | Colorectal Neoplasms NIH | 0.16 |
| D008180 | Lupus Erythematosus, Systemic NIH | 0.14 |
| D008175 | Lung Neoplasms NIH | 0.10 |
| D006973 | Hypertension NIH | 0.07 |
| D003866 | Depressive Disorder NIH | 0.07 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
| D009369 | Neoplasms, NIH | 0.06 |
| D018352 | Coronavirus Infections NIH | 0.05 |
| D003863 | Depression, NIH | 0.04 |
| D013577 | Syndrome NIH | 0.03 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.03 |
| D055371 | Acute Lung Injury NIH | 0.03 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.03 |
| D003141 | Communicable Diseases NIH | 0.03 |
| D007239 | Infection NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100574 | Biliary tract neoplasm HPO | 0.35 |
| HP:0009725 | Bladder neoplasm HPO | 0.35 |
| HP:0100723 | Gastrointestinal stroma tumor HPO | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100754 | Mania HPO | 0.25 |
| HP:0100614 | Myositis HPO | 0.25 |
| HP:0100834 | Neoplasm of the large intestine HPO | 0.16 |
| HP:0002725 | Systemic lupus erythematosus HPO | 0.14 |
| HP:0100526 | Neoplasm of the lung HPO | 0.10 |
| HP:0000822 | Hypertension HPO | 0.07 |
| HP:0000716 | Depressivity HPO | 0.07 |
| HP:0002664 | Neoplasm HPO | 0.06 |
Navigate: Correlations HPO
There are 8 clinical trials
SARS-CoV-2, one of a family of human coronaviruses, was initially identified in December 2019 in Wuhan city. This new coronavirus causes a disease presentation which has now been named COVID-19. The virus has subsequently spread throughout the world and was declared a pandemic by the World Health Organisation on 11th March 2020. As of 18 March 2020, there are 198,193 number of confirmed cases with an estimated case-fatality of 3%. There is no approved therapy for COVID-19 and the current standard of care is supportive treatment. SARS-CoV-2 exploits the cell entry receptor protein angiotensin converting enzyme II (ACE-2) to access and infect human cells. The interaction between ACE2 and the spike protein is not in the active site. This process requires the serine protease TMPRSS2. Camostat Mesilate is a potent serine protease inhibitor. Utilizing research on severe acute respiratory syndrome coronavirus (SARS-CoV) and the closely related SARS-CoV-2 cell entry mechanism, it has been demonstrated that SARS-CoV-2 cellular entry can be blocked by camostat mesilate. In mice, camostat mesilate dosed at concentrations similar to the clinically achievable concentration in humans reduced mortality following SARS-CoV infection from 100% to 30-35%.
Description: Clinical improvement defined as live hospital discharge OR a 2 point improvement (from time of enrolment) in disease severity rating on the 7-point ordinal scale
Measure: Cohort 1: Days to clinical improvement from study enrolment Time: 30 daysDescription: Days to clinical improvement from study enrolment defined no fever for at least 48 hrs AND improvement in other symptoms (e.g. cough, expectoration, myalgia, fatigue, or head ache)
Measure: Cohort 2: Days to clinical improvement from study enrolment Time: 30 daysDescription: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.
Measure: Cohort 1: Clinical status as assessed by the 7-point ordinal scale at day 7, 14 and 30 Time: 30 daysDescription: Mortality
Measure: Cohort 1: Day 30 mortality Time: 30 daysDescription: NEWS2
Measure: Cohort 1: Change in NEW(2) score from baseline to day 30 Time: 30 daysDescription: ICU
Measure: Cohort 1: Admission to ICU Time: 30 daysDescription: invasive mechanical ventilation or ECMO
Measure: Cohort 1: Use of invasive mechanical ventilation or ECMO Time: 30 daysDescription: Nasal or high-flow oxygen
Measure: Cohort 1: Duration of supplemental oxygen (days) Time: 30 daysDescription: Subjective clinical improvement
Measure: Cohort 1+2: Days to self-reported recovery (e.g. limitations in daily life activities) during telephone interviews conducted at day 30 Time: 30 daysDescription: No of new COVID-19 infections in the household
Measure: Cohort 2: Number participant-reported secondary infection of housemates Time: 30 daysDescription: Hospital admission
Measure: Cohort 2: Time to hospital admission related to COVID-19 infection Time: 30 daysEvaluation of the efficacy and safety of hydroxychloroquine - camostat combination therapy in hospitalized patients with moderate COVID-19 infection, CLOCC-Trial Primary Objectives: The primary objective of this study is to demonstrate, that a combination therapy of hydroxychloroquine and camostat (Foipan®) is superior to hydroxychloroquine + placebo in participants with moderate COVID-19.
The rationale of the present clinical trial is that an orally available drug given to outpatients that could reduce the viral burden in the upper respiratory tract could forestall complications of SARS-CoV-2 infection and reduce transmission from one infected individual to another.
Description: To determine whether camostat mesylate reduces SARS-COV-2 viral load in early COVID-19 disease, change from day 0 to day 4 in respiratory (oropharyngeal swab RT-PCR) log10 viral load will be assessed.
Measure: Change in SARS-COV-2 viral load Time: 5 daysDescription: To determine whether camostat mesylate reduces SARS-COV-2 viral load in early COVID-19 disease, change from day 0 to day 2 in respiratory (oropharyngeal swab RT-PCR) log10 viral load will be assessed.
Measure: Change in SARS-COV-2 viral load Time: 3 daysDescription: To determine whether camostat mesylate reduces SARS-COV-2 viral load in early COVID-19 disease, change from day 0 to day 6 in respiratory (oropharyngeal swab RT-PCR) log10 viral load will be assessed.
Measure: Change in SARS-COV-2 viral load Time: 7 daysDescription: Change in risk for a positive COVID-19 test at day 6 after enrollment (day 0) will be assessed by analyzing the proportion of positive cases in each study arm.
Measure: Change in positive COVID-19 status Time: 7 daysDescription: Change of COVID-19 symptom severity from day 0 to day 6 will be assessed with the COVID-19 daily self score tool. Adapted from the FLU-PRO instrument, it consists of 39 items that are answered daily. Items 1-33 are Likert scale questions (rated 0-4) where 0 = not at all and 4 = very much. These items are summed to score the severity of symptoms- where a total score of 132 would indicate the greatest severity of symptoms and a score of 0 would indicate no severity of symptoms. Items 34-38 are also Likert scale questions (rated 0-4) that measure the frequency of specific daily symptoms where 0 = 0 times and 4 = 4 times or more. These items are summed to score the frequency of symptoms- where the highest score for the frequency of symptoms (20) indicates the greatest burden of symptom frequency. The last question (39) asks patients for their highest temperature in Fahrenheit.
Measure: Change in COVID-19 symptom severity Time: 7 daysDescription: Change of COVID-19 symptom severity from day 0 to day 14 will be assessed with the COVID-19 daily self score tool. Adapted from the FLU-PRO instrument, it consists of 39 items that are answered daily. Items 1-33 are Likert scale questions (rated 0-4) where 0 = not at all and 4 = very much. These items are summed to score the severity of symptoms- where a total score of 132 would indicate the greatest severity of symptoms and a score of 0 would indicate no severity of symptoms. Items 34-38 are also Likert scale questions (rated 0-4) that measure the frequency of specific daily symptoms where 0 = 0 times and 4 = 4 times or more. These items are summed to score the frequency of symptoms- where the highest score for the frequency of symptoms (20) indicates the greatest burden of symptom frequency. The last question (39) asks patients for their highest temperature in Fahrenheit.
Measure: Change in COVID-19 symptom severity Time: 14 daysDescription: Change of COVID-19 symptom score from day 0 to day 6 will be assessed with the COVID-19 daily self score tool. Adapted from the FLU-PRO instrument, it consists of 39 items that are answered daily. Items 1-33 are Likert scale questions (rated 0-4) where 0 = not at all and 4 = very much. These items are summed to score the severity of symptoms- where a total score of 132 would indicate the greatest severity of symptoms and a score of 0 would indicate no severity of symptoms. Items 34-38 are also Likert scale questions (rated 0-4) that measure the frequency of specific daily symptoms where 0 = 0 times and 4 = 4 times or more. These items are summed to score the frequency of symptoms- where the highest score for the frequency of symptoms (20) indicates the greatest burden of symptom frequency. The last question (39) asks patients for their highest temperature in Fahrenheit.
Measure: Change in COVID-19 symptom frequency Time: 7 daysDescription: Change of COVID-19 symptom score from day 0 to day 14 will be assessed with the COVID-19 daily self score tool. Adapted from the FLU-PRO instrument, it consists of 39 items that are answered daily. Items 1-33 are Likert scale questions (rated 0-4) where 0 = not at all and 4 = very much. These items are summed to score the severity of symptoms- where a total score of 132 would indicate the greatest severity of symptoms and a score of 0 would indicate no severity of symptoms. Items 34-38 are also Likert scale questions (rated 0-4) that measure the frequency of specific daily symptoms where 0 = 0 times and 4 = 4 times or more. These items are summed to score the frequency of symptoms- where the highest score for the frequency of symptoms (20) indicates the greatest burden of symptom frequency. The last question (39) asks patients for their highest temperature in Fahrenheit.
Measure: Change in COVID-19 symptom frequency Time: 14 daysDescription: Change of COVID-19 symptom score from baseline to day 6 will be assessed with the COVID-19 daily self score tool. Adapted from the FLU-PRO instrument, it consists of 39 items that are answered daily. Items 1-33 are Likert scale questions (rated 0-4) where 0 = not at all and 4 = very much. These items are summed to score the severity of symptoms- where a total score of 132 would indicate the greatest severity of symptoms and a score of 0 would indicate no severity of symptoms. Items 34-38 are also Likert scale questions (rated 0-4) that measure the frequency of specific daily symptoms where 0 = 0 times and 4 = 4 times or more. These items are summed to score the frequency of symptoms- where the highest score for the frequency of symptoms (20) indicates the greatest burden of symptom frequency. The last question (39) asks patients for their highest temperature in Fahrenheit.
Measure: Change in body temperature Time: 7 daysDescription: Change of COVID-19 symptom score from baseline to day 14 will be assessed with the COVID-19 daily self score tool. Adapted from the FLU-PRO instrument, it consists of 39 items that are answered daily. Items 1-33 are Likert scale questions (rated 0-4) where 0 = not at all and 4 = very much. These items are summed to score the severity of symptoms- where a total score of 132 would indicate the greatest severity of symptoms and a score of 0 would indicate no severity of symptoms. Items 34-38 are also Likert scale questions (rated 0-4) that measure the frequency of specific daily symptoms where 0 = 0 times and 4 = 4 times or more. These items are summed to score the frequency of symptoms- where the highest score for the frequency of symptoms (20) indicates the greatest burden of symptom frequency. The last question (39) asks patients for their highest temperature in Fahrenheit.
Measure: Change in body temperature Time: 14 daysThis is a multi-arm, phase II trial for rapid efficacy and toxicity assessment of multiple therapies immediately after COVID19 positive testing in high-risk individuals. Therapies include stand-alone or combination treatment with hydroxychloroquine, azithromycin, ivermectin, or camostat mesilate, artemesia annua. The hypothesis of this study is that the addition of agents that inhibit viral entry or replication of SARS-CoV-2 virus replication in will be devoid of additional moderate to severe toxicities, will prevent clinical deterioration, and will improve viral clearance in high risk individuals.
Description: Proportion of patients experiencing clinical deterioration. Clinical deterioration is defined as a less than a 2-point change from the initial COVID 7-Point Ordinal Outcomes Scale within 14 days from the study start. This scale ranges from 1-7. Lower scores indicate worse outcomes (death); higher scores indicate fewer symptoms and better outcomes.
Measure: Clinical Deterioration Time: 14 daysDescription: The change in (clearance of) viral RNA will be measured by PCR testing at days 1, 14, 28, and 40 days.
Measure: Change in Viral Load Time: 40 daysDescription: Percentage of patients that experience severe respiratory or other organ failure.
Measure: Rate of Organ Failure Time: 28 daysDescription: Percentage of patients requiring ICU admission or ventilation.
Measure: Progression to ICU Care or Ventilation Time: 28 daysDescription: Clinical status will be assessed using the COVID 7-Point Ordinal Outcomes Scale. This scale ranges from 1-7. Lower scores indicate worse outcomes; higher scores indicate fewer symptoms and better outcomes.
Measure: Change in Clinical Status Time: 14 daysDescription: Percentage of patients who have died by day 14.
Measure: Mortality Time: 14 daysDescription: Percentage of patients experiencing severe adverse events, defined as grade 3 non-hematologic or greater by DMID Toxicity Scale for Determining Severity of Adverse Events.
Measure: Rate of severe adverse events Time: 14 daysDescription: Number of days patients do not require oxygen supplementation.
Measure: Oxygen-free days Time: 28 daysDescription: Number of days patients do not require mechanical ventilation.
Measure: Ventilator-free days Time: 28 daysDescription: Number of days patients do not require vasopressor treatment.
Measure: Vasopressor-free days Time: 28 daysDescription: Number of days patients do not require ICU services.
Measure: ICU-free days Time: 28 daysDescription: Number of days patients do not require hospitalization.
Measure: Hospital-free days Time: 28 daysDescription: Proportion of patients meeting Hy's law criteria.
Measure: Patients meeting Hy's Law criteria Time: 28 daysDescription: Proportion of patients with changes in the following liver function tests: Any ALT or AST ≥ 5 x ULN; any AST or ALT ≥ 3 x ULN together with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash and/or eosinophilia (eosinophil percent or count above the ULN); Persistent ALT ≥ 3 x ULN for a period of more than 4 weeks
Measure: Liver Function Time: 28 daysDescription: Proportion of patients with significant changes in ECG findings, including heart rate, ECG intervals (PR, QTcB, QTcF), conduction changes, or abnormalities including severe QTc prolongation of > 500 ms.
Measure: Heart Function Time: 28 daysTo determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.
Description: To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will change the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.
Measure: Change in the proportion of patients alive and free from respiratory failure Time: 28 DaysDescription: To determine if reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with SOC treatment will change the proportion of patients alive and free of ventilator use or ECMO at Day 28 as compared to SOC treatment combined with placebo.
Measure: Change in the proportion of patients alive and free of ventilator use or ECMO Time: 28 DaysDescription: To determine if the combination of Camostat mesilate combined with SOC treatment will result in a changed mortality rate at 28 and 56 days as compared to SOC treatment combined with placebo.
Measure: Mortality Rate Time: 28 and 56 DaysDescription: Clinical change will be defined as a 2 or more point decease on the WHO ordinal scale. Time to clinical improvement will be calculated as the number of days from study entry until the earliest date of clinical change.
Measure: Clinical Change Time: 14 and 28 DaysDescription: Analyses for safety will include all participants who are randomized and received at least 1 dose of study treatment. Participants will be grouped according to the treatment to which they were randomized.
Measure: Adverse Events Time: up to 56 daysThis study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild-moderate COVID-19 disease. Patients will attend 4 study visits over a period of up to 28 days.
Description: This outcome is defined as the time in days from randomization to the first of two consecutive negative RT-PCR results of self-collected nasal swabs.
Measure: Time until cessation of shedding of SARS-CoV-2 virus Time: Up to 28 daysDescription: Number of symptomatic patients with clinical worsening, defined as the development of respiratory distress or symptoms that require hospitalization.
Measure: Clinical worsening of COVID-19 disease in symptomatic patients Time: Up to 28 daysDescription: Number of patients that develop antibodies to SARS-CoV-2.
Measure: Development of antibodies to SARS-CoV-2 Time: Up to 28 daysDescription: This outcome is defined as absence of moderate or severe symptoms for at least 24 hours for those reporting moderate or severe symptoms at baseline
Measure: Time until resolution of symptoms Time: Up to 28 daysDescription: Progression of respiratory symptoms defined as a two-level increase of a symptom on the Daily Symptom Status Questionnaire within a 24 hour period, or a one-level increase of a symptom on the Daily Symptom Status Questionnaire observed/sustained for a consecutive 48 hour period.
Measure: Time until progression of symptoms Time: Up to 28 daysThis is a randomized, double-blind, placebo-controlled, multi-arm, multicenter, phase II trial design to allow a rapid efficacy and toxicity assessment of potential therapies (camostat mesilate and artemisia annua) immediately after COVID-19 positive testing in mild to moderate disease and high-risk factors such as diabetes, hypertension, and obesity among others.
Description: Decrease in a composite outcome of hospitalization and supplemental oxygen use at day 14 between treatment pairs.
Measure: Rate of hospitalizations and oxygen use Time: 14 daysThis is a randomized, double-blind, placebo-controlled study of camostat mesilate in ambulatory patients with confirmed COVID-19 with at least one risk factor for severe illness.
Description: Disease progression will be defined as the proportion of participants requiring hospitalization (including emergency room visit) or who die due to any cause within 28 days of randomization.
Measure: Disease Progression at Day 28 Time: 28 daysDescription: The overall survival rate (the proportion of randomized participants who survive up to Day 15 and Day 28).
Measure: Survival Rate Time: Up to Day 15 and Day 28Description: Time (in hours) from initiation of study treatment until normalization of fever (≤ 37.2 °C oral or tympanic) and sustained for at least 72 hours only assessed in participants who experienced a fever within 24 hours of enrollment up to Day 28.
Measure: Time to Fever Resolution Time: Up to 28 daysDescription: Time to disease progression is defined as the time from randomization to either hospitalization or death up to Day 28.
Measure: Time to Disease Progression Time: Up to 28 daysDescription: Proportion of participants with no viral shedding (yes/no) using reverse transcriptase-polymerase chain reaction (RT-PCR) at Day 7, Day 15, and at early termination.
Measure: Resolution of Viral Shedding Time: Day 1, Day 7 and Day 15Description: Incidence of adverse events (AEs) and serious adverse events (SAEs) of any grade from randomization up to Day 28.
Measure: Rate of Adverse Events and Serious Adverse Events Time: 28 daysDescription: Cumulative incidence of grade 3 and 4 AEs from randomization up to Day 28.
Measure: Cumulative Rate of Grade 3 and 4 Adverse Events Time: 28 daysDescription: Incidence of discontinuation from study due to an AE/SAE (discontinued participants will be followed up to Day 28).
Measure: Rate of Discontinuation Time: 28 daysDescription: Change from baseline in clinical laboratory value of platelet count.
Measure: Change in Laboratory Parameter - Platelet Count Time: Day 1 and Day 15Description: Change from baseline in clinical laboratory value of potassium level.
Measure: Change in Laboratory Parameter - Potassium Level Time: Day 1 and Day 15Description: Change from baseline in clinical laboratory value of AST.
Measure: Change in Laboratory Parameter - Aspartate Aminotransferase (AST) Time: Day 1 and Day 15Description: Change from baseline in clinical laboratory value of ALT.
Measure: Change in Laboratory Parameter - Alanine Aminotransferase (ALT) Time: Day 1 and Day 15Description: Change from baseline in clinical laboratory value of ALP.
Measure: Change in Laboratory Parameter - Alkaline Phosphatase (ALP) Time: Day 1 and Day 15Description: Change from baseline in clinical laboratory value of GGT.
Measure: Change in Laboratory Parameter - Gamma-Glutamyl Transferase (GGT) Time: Day 1 and Day 15Description: Change from baseline in clinical laboratory value of albumin.
Measure: Change in Laboratory Parameter - Albumin Time: Day 1 and Day 15Description: Change from baseline in clinical laboratory value of bilirubin.
Measure: Change in Laboratory Parameter - Bilirubin Time: Day 1 and Day 15Description: Change from baseline in heart rate.
Measure: Change in Vital Signs - Heart Rate Time: Day 1, Day 7 and Day 15Description: Change from baseline in blood pressure.
Measure: Change in Vital Signs - Blood Pressure Time: Day 1, Day 7 and Day 15Description: Change from baseline in SpO2.
Measure: Change in Vital Signs - Peripheral Capillary Oxygen Saturation (SpO2) Time: Day 1, Day 7 and Day 15Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports